Analysis On The Merger And Acquisition Performance Of China's Bio-pharmaceutical Companies

The improvement of the national market economic system has made the competition among enterprises increasingly tight.It is difficult for enterprises to rapidly increase their strength in the short term by their own development,and mergers and acquisitions are an important strategic way to accelerate industrial transformation and optimization and promote enterprises to adapt to the current economic environment and development.In recent years,the number of mergers and acquisitions in the Chinese pharmaceutical industry has continued to increase,and the amount involved in mergers and acquisitions has increased year by year.As one of the seven newly emerging industries,the blood product industry occupies an important position in the bio-pharmaceutical industry.The blood product industry in terms of its nature in the entire medical field is not only highly technical,but also accompanied by high risks and benefits.As the medical industry's demand for blood products has gradually increased,the blood product industry has ushered in the spring of development.In order for companies to quickly increase their own strength in this environment,expansion of mergers and acquisitions is particularly important.On the one hand,the plasma of healthy people is originally a precious resource,and the share of the pulp source has a great influence on the development of the company or even its survival.On the one hand,compared with the international market for blood products,China's blood product companies have emerged as a monopoly under the guidance of market demand.Based on the above,M&A is the most effective way to increase competitiveness.This article describes the development status of China's blood products industry,and briefly outlines the basic situation of mergers and acquisitions as well as mergers and acquisitions process.Based on the relevant literature research on the causes of mergers and acquisitions,it analyzes the causes of mergers and acquisitions;it uses event research methods,financial indicators,The EVA Law et al.conducted a detailed analysis of the short-term market response and long-term performance of the merger and acquisition,and compared it with similar companies in the same industry by using spss software factor analysis method to evaluate its comprehensive ranking before and after the merger and acquisition and obtained the merger and acquisition event.Regardless of whether it is obvious for Shanghai Lai Shi or Tong Lun biological,the synergies can be brought into full play,consolidating the position of Shanghai Lai Shi in the industry,and at the same time providing valuable inspiration for other similarly sized blood product companies.